Morningstar

AbbVie's Skyrizi Gets FDA Approval For Pediatric Use

Provided by Dow Jones

By Stephen Nakrosis 




   Pharmaceutical maker AbbVie said the Food and Drug Administration approved its Skyrizi to treat pediatric patients with psoriasis. 



  Skyrizi, or risankizumab-rzaa, will be available to patients aged six years and older to treat moderate-to-severe plaque psoriasis or active psoriatic arthritis, the company said. A new 55 mg pre-filled syringe has been approved for patients weighing less than 40 kg, or about 88 lbs, while those over that weight may use the currently available 150 mg PFS and Pen. 



  AbbVie said about 30% of people who develop psoriasis experience symptoms before age 18. 



  Skyrizi is also used to treat adults with moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn's disease, and moderate to severe ulcerative colitis, AbbVie said. 





  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com 





  (END) Dow Jones Newswires



  June 26, 2026 17:21 ET (21:21 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
5 Stocks to Buy Trading at Big Discounts
 
Plus, what recent bond market volatility means for investors. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
 
Defense spending and booming data center demand could provide powerful tailwinds for these 4-star stocks. 
 
 
David Sekera, CFA, Sarah Hansen, and Jess Bebel 
 
 
 
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
 
Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons for optimism. 
 
 
Karen Andersen, CFA 
 
 
 
What 7 Key Market Indicators Are Telling Investors Right Now
 
US equity valuations have retreated from their recent highs, but all 7 major market indicators remain above their long-term averages. 
 
 
Amy C. Arnott, CFA 
 
 
 
There Are Three Paths Forward for the AI Boom. Two of Them Lead to Lower Interest Rates
 
Mass layoffs or a spending slowdown would likely require hefty Fed rate cuts. 
 
 
Preston Caldwell 
 
 
 
 

			Sponsor Center